Journal Logo

Most Popular Articles

MALDI-TOF Mass Spectrometry: Getting a Feel for How It Works

Tuma, Rabiya S. PhD

Oncology Times. 25(19):26, October 10, 2003.

The ABCs of the powerful mass-spectrometry technique of “matrix-assisted laser desorption ionization time-of-flight.”

The Rhoads Not Given: The Tainting of the Cornelius P. Rhoads Memorial Award

Rosenthal, Eric T.

Oncology Times. 25(17):19-20, September 10, 2003.

What happens when an organization learns that one of its long-established, prestigious awards was named for an individual of less-than-sterling reputation? Here's how AACR faced that dilemma.

Treating Lower-Body Lymphedema

West, Diane

Oncology Times. 26(9):4,7, May 10, 2004.

A look at an often forgotten type of problem, associated with prostate, stomach, ovarian, or colon cancer surgery. Lymphedema after cancer surgery to the lower body can cause swelling to the stomach and genitals as well as swelling in the legs and feet leading to loss of mobility and severe swelling.

Oral Anabolic Steroid Effective for Cancer Cachexia

Laino, Charlene

Oncology Times. 25(12):15-16, June 25, 2003.

Oxandrolone can help cancer patients with involuntary weight loss gain lean body mass, while improving quality of life and performance status, according to a preliminary prospective study, which suggests it also helps reverse the underlying pathology, improving metabolically active tissue compartments.

Ovarian Cancer: Adjuvant Chemo Reduces Recurrence, But So Does Adequate Staging

Carlson, Robert H.

Oncology Times. 25(6):5-7, March 25, 2003.

The standard of care for high-risk early ovarian cancer is adjuvant chemotherapy after surgery, but the big question is which patients are at high risk, something that is not always obvious. The large ACTION and ICON1 European Phase III studies have now been reported, but the question remains open.

Anemia Hard Choices: Comparing Procrit vs Aranesp

Henkel, Gretchen

Oncology Times. 25(6):29-30,32-33, March 25, 2003.

With no clear consensus about one drug being superior to the other, the Centers for Medicare & Medicaid Services, researchers, and drug companies are all weighing in on what may be an “apples vs oranges” debate.

Show: